SPI 119

Drug Profile

SPI 119

Alternative Names: CD4 liposomal; liposome-CD4 technology; RBC CD4 liposomal

Latest Information Update: 26 Feb 2008

Price : $50

At a glance

  • Originator Sheffield Pharmaceuticals
  • Developer ALZA Corporation
  • Class Antivirals
  • Mechanism of Action CD4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 28 Jun 2001 ALZA Corporation has been acquired by Johnson & Johnson
  • 07 Sep 2000 Sheffield Pharmaceticals is no longer involved in the development of SPI 119
  • 23 Apr 1999 Sequus has been merged into ALZA Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top